Floatz logo

Alemtuzumab

Relapsing-Remitting Multiple Sclerosis

Universitätsklinikum Hamburg-Eppendorfmonoclonal_antibodyPhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
81/ 100

Competitive context

70 Active assets in the Relapsing-Remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Fingolimod
TG Therapeutics, Inc.
Phase 4BBB
Natalizumab
Biogen
Phase 4BBB
Interferon ?1 (Human Fibroblast Protein Moiety)
Biogen
Phase 4BBB
Ocrelizumab
Biocad
Phase 4BBB

View all 50 →

Same molecule, other indications

Alemtuzumab is also rated in:

myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative · Phase 2
71 / 100
View asset →
chronic myeloid leukemiaActive
BB
Indicative · Phase 2/3
71 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →